Info: Read More
  • 中药标准品生产商,产品定制服务
  • 孕酮; 黄体素; 黄体酮

    Progesterone

    孕酮; 黄体素; 黄体酮
    产品编号 CFN90039
    CAS编号 57-83-0
    分子式 = 分子量 C21H30O2 = 314.46
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Steroids
    植物来源
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    孕酮; 黄体素; 黄体酮 CFN90039 57-83-0 10mg QQ客服:2056216494
    孕酮; 黄体素; 黄体酮 CFN90039 57-83-0 20mg QQ客服:2056216494
    孕酮; 黄体素; 黄体酮 CFN90039 57-83-0 50mg QQ客服:2056216494
    孕酮; 黄体素; 黄体酮 CFN90039 57-83-0 100mg QQ客服:2056216494
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • University of Bordeaux (France)
  • Universiti Malaysia Pahang (Malaysia)
  • Cancer Research Initatives Foundation(CARIF) (Malaysia)
  • University of Cincinnati (USA)
  • FORTH-IMBB (Greece)
  • Gyeongsang National University (Korea)
  • Institute of Chinese Materia Medica (China)
  • University of Oslo (Norway)
  • Warszawski Uniwersytet Medyczny (Poland)
  • University of Illinois (USA)
  • University of Canterbury (New Zealand)
  • University of Indonesia (Indonesia)
  • Molecular Biology Institute of Barcelona (IBMB)-CSIC (Spain)
  • University of Helsinki (Finland)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Planta Med.2023, 2192-2281
  • Front Immunol. 2020, 11:62.
  • J Chromatogr Sci.2020, 58(6):485-493.
  • Int J Biol Macromol.2020, 169:342-351
  • BMC Cancer. 2021, 21(1):91.
  • Front Pharmacol.2022, 13:870553.
  • Food Sci Nutr.2023, 11(9):5532-5542.
  • J of Pharmaceutical Analysis2020, doi: 10.1016
  • Nutrients.2021, 13(3):978.
  • Phytother Res.2019, 33(7):1784-1793
  • Mol Immunol. 2016, 78:121-132
  • Phytomedicine.2019, 55:229-237
  • Tumour Biol.2015, 36(12):9385-93
  • Tropical J. of Pha. Research2017, 16(3):543-552
  • Preprints2022, 2022030063.
  • Biomolecules.2023, 13(2):227.
  • Asian J of Pharmaceutical&Clinical 2018, 11(2)
  • US20170000760 A12016, 42740
  • Front Pharmacol.2016, 7:460
  • Molecules.2022, 27(5):1675
  • Horticulturae2022, 8(10), 975.
  • ACS Synth Biol.2022, doi: 10.1021.
  • Int J Mol Sci.2022, 23(23):14826.
  • ...
  • 生物活性
    Description: Progesterone is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor. Stimulation of breast cell tumorigenesis and tumor growth accompanying Progesterone treatment is due to the Progesterone metabolite 5αP, and that breast tumorigenesis can be blocked with the 5α-reductase inhibitor, finasteride.
    Targets: COX | PKA | MEK
    In vitro:
    J Endocrinol. 2015 Feb;224(2):183-94.
    Progesterone-induced activation of membrane-bound progesterone receptors in murine macrophage cells.[Pubmed: 25472814 ]
    Parturition is an inflammatory process mediated to a significant extent by macrophages. Progesterone (P4) maintains uterine quiescence in pregnancy, and a proposed functional withdrawal of P4 classically regulated by nuclear progesterone receptors (nPRs) leads to labor. P4 can affect the functions of macrophages despite the reported lack of expression of nPRs in these immune cells.
    METHODS AND RESULTS:
    Therefore, in this study we investigated the effects of the activation of the putative membrane-associated PR on the function of macrophages (a key cell for parturition) and discuss the implications of these findings for pregnancy and parturition. In murine macrophage cells (RAW 264.7), activation of mPRs by P4 modified to be active only extracellularly by conjugation to BSA (P4BSA, 1.0×10(-7) mol/l) caused a pro-inflammatory shift in the mRNA expression profile, with significant upregulation of the expression of cyclooxygenase 2 (COX2 (Ptgs2)), Il1B, and Tnf and downregulation of membrane progesterone receptor alpha (Paqr7) and oxytocin receptor (Oxtr). Pretreatment with PD98059, a MEK1/2 inhibitor, significantly reduced P4BSA-induced expression of mRNA of Il1B, Tnf, and Ptgs2. Inhibition of protein kinase A (PKA) by H89 blocked P4BSA-induced expression of Il1B and Tnf mRNA. P4BSA induced rapid phosphorylation of MEK1/2 and CREB (a downstream target of PKA). This phosphorylation was inhibited by pretreatment with PD98059 and H89, respectively, revealing that MEK1/2 and PKA are two of the components involved in mPR signaling.
    CONCLUSIONS:
    Taken together, these results indicate that changes in membrane progesterone receptor alpha expression and signaling in macrophages are associated with the inflammatory responses; and that these changes might contribute to the functional withdrawal of P4 related to labor.
    In vivo:
    J Steroid Biochem Mol Biol. 2015 Mar;147:31-9.
    Progesterone-induced down-regulation of hormone sensitive lipase (Lipe) and up-regulation of G0/G1 switch 2 (G0s2) genes expression in inguinal adipose tissue of female rats is reflected by diminished rate of lipolysis.[Pubmed: 25448749]
    Decreased lipolytic activity in adipose tissue may be one of the reasons behind excess accumulation of body fat during pregnancy.
    METHODS AND RESULTS:
    The aim of this study was to analyze the effect of progesterone on the expression of: (a) Lipe (encoding hormone-sensitive lipase, HSL), (b) Pnpla2 (encoding adipose triglyceride lipase, ATGL), (c) abhydrolase domain containing 5 (Abhd5), and (d) G0/G1 switch 2 (G0s2) genes in white adipose tissue (WAT), as potential targets for progesterone action during the course of pregnancy. Administration of progesterone to female rats, which was reflected by approximately 2.5-fold increase in circulating progesterone concentration, is associated with a decrease in Lipe gene expression in the inguinal WAT. The expression of Pnpla2 gene in all main fat depots of females and males remained unchanged after progesterone administration. Administration of progesterone resulted in an increase in the expression of Abhd5 gene (whose product increases ATGL activity) and G0s2 gene (whose product decreases ATGL activity) in the inguinal WAT of female rats. Mifepristone, a selective antagonist of progesterone receptor, abolished the effect of progesterone on Lipe, Abhd5 and G0s2 genes expression in the inguinal WAT. The decrease in Lipe and the increase in Abhd5 and G0s2 genes expression was associated with lower rate of stimulated lipolysis. Administration of progesterone exerted no effect on Lipe, Abhd5 and G0s2 genes expression and stimulated lipolysis in the retroperitoneal WAT of females, as well as in the inguinal, epididymal and retroperitoneal WAT of males.
    CONCLUSIONS:
    In conclusion, our findings suggest that progesterone decreases the rate of lipolysis in the inguinal WAT of female rats, inhibiting the activity of both ATGL (by stimulating synthesis of G0S2 - specific inhibitor of the enzyme) and HSL (due to inhibition of Lipe gene expression).
    Am J Obstet Gynecol. 2015 Mar;212(3):335.e1-7.
    Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study.[Pubmed: 25305408]
    Nuchal translucency (NT) seen ultrasonographically at 11-14 weeks' gestation is a sensitive marker for Down syndrome. Despite its important role for Down syndrome screening, its use is still considered controversial due to high false-positive rates. We speculated that progesterone could lead to abnormal blood flow patterns and, subsequently, to increased NT. Our primary endpoint was to evaluate the effects of exogenous progesterone on NT thickness compared to controls. The secondary endpoint was to evaluate these effects in a subgroup at low risk for fetal aneuploidies, identifying the strongest factors influencing NT variation. The tertiary endpoint was to evaluate, within the treatment group, if there is any difference in NT according to the type of progesterone administered, route of administration, and dose regimen.
    METHODS AND RESULTS:
    All women who came to measure NT at 11-14 weeks' gestation (crown-rump length between 45-84 mm) were considered eligible. We divided patients into 2 groups: women receiving exogenous progesterone and controls. Afterwards, 3 NT scans were performed for each case, and the largest value, accurate to 2 decimal points, was recorded. In all, 3716 women were enrolled and analyzed. In a crude analysis, NT (P < .05) increased in the exogenous progesterone group. The same results were obtained in the low-risk group (P < .05). The factorial analysis of variance model confirmed a correlation between altered NT and gestational age (P < .0001) and progesterone exposure (P < .05). The characteristics of treatment (route, formulation, dose) were examined separately and no statistically significant differences among the subgroups were observed.
    CONCLUSIONS:
    Exogenous progesterone increases NT.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.1801 mL 15.9003 mL 31.8005 mL 63.6011 mL 79.5014 mL
    5 mM 0.636 mL 3.1801 mL 6.3601 mL 12.7202 mL 15.9003 mL
    10 mM 0.318 mL 1.59 mL 3.1801 mL 6.3601 mL 7.9501 mL
    50 mM 0.0636 mL 0.318 mL 0.636 mL 1.272 mL 1.59 mL
    100 mM 0.0318 mL 0.159 mL 0.318 mL 0.636 mL 0.795 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    孕烯醇酮; Pregnenolone CFN99497 145-13-1 C21H32O2 = 316.5 20mg QQ客服:2159513211
    孕酮; 黄体素; 黄体酮; Progesterone CFN90039 57-83-0 C21H30O2 = 314.46 20mg QQ客服:2159513211
    6,7-二羟基欧奕二烯酮A; 6,7-Dihydroneridienone A CFN96120 72959-46-7 C21H28O3 = 328.5 5mg QQ客服:2159513211
    11β-羟基黄体酮; 11Beta-hydroxyprogesterone CFN90052 600-57-7 C21H30O3 = 330.46 20mg QQ客服:3257982914
    氢化可的松; Hydrocortisone CFN90033 50-23-7 C21H30O5 = 362.46 20mg QQ客服:2159513211
    肾上腺酮; Corticosterone CFN90044 50-22-6 C21H30O4 = 346.46 20mg QQ客服:215959384
    欧奕二烯酮B; Neridienone B CFN97057 61671-56-5 C21H28O4 = 344.5 5mg QQ客服:1413575084
    21-去氧基欧奕二烯酮; 21-Deoxyneridienone B CFN97487 924910-83-8 C21H28O3 = 328.5 5mg QQ客服:1457312923

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产